Plasma levels of IL-37 and correlation with TNF-a, IL-17A, and Disease activity during DMARD treatment of rheumatoid arthritis

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Zhao, Ping Wei ^a   Jiang, Wei Guang ^a   Wang, Li ^a   Jiang, Zhen Yu ^a   Shan, Yu Xing ^a   Jiang, Yan Fang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 37; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; SMAD3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; IL37 PROTEIN, HUMAN; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922212387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095346     Document Type: Article

References (32)

1. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376:1094-1108.
2. Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, et al. (2012) IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 10:e1001395.
3. Chu K, Zheng H, Li H, Zhang Y, Zhang X, et al. (2013) Shuangtengbitong tincture treatment of collagen-induced arthritis via downregulation of the expression of IL-6, IL-8, TNF-alpha and NF-kappaB. Exp Ther Med 5:423-428.
4. Hashizume M, Mihara M (2011) The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011:765624.
5. Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, et al. (2007) IL-6 programs T (H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967-974.
6. Park JY, Pillinger MH (2007) Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 65 Suppl 1:S4-10.
7. Kurebayashi Y, Nagai S, Ikejiri A, Koyasu S (2013) Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes Cells 18:247-265.
8. van Hamburg JP, Corneth OB, Paulissen SM, Davelaar N, Asmawidjaja PS, et al. (2013) IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis.
9. Lubberts E, van den Berg WB (2003) Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol 520:194-202.
10. Sharma S, Kulk N, Nold MF, Graf R, Kim SH, et al. (2008) The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 180:5477-5482.
11. Dunn E, Sims JE, Nicklin MJ, O'Neill LA (2001) Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 22:533-536.
12. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, et al. (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 22:127-147.
13. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, et al. (2010) IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 11:1014-1022.
14. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, et al. (2011) Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol 127:701-721 e701-770.
15. Simon LS (2000) DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. Int J Clin Pract 54:243-249.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48.
18. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, et al. (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110:252-266.
19. Tarnok A, Hambsch J, Chen R, Varro R (2003) Cytometric bead array to measure six cytokines in twenty-five microliters of serum. Clin Chem 49:1000-1002.
20. Biswas S, Sharma S, Saroha A, Bhakuni DS, Malhotra R, et al. (2013) Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach. PLoS One 8:e56246.
21. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440.
22. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-442.
23. Bufler P, Azam T, Gamboni-Robertson F, Reznikov LL, Kumar S, et al. (2002) A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 99:13723-13728.
24. Tete S, Tripodi D, Rosati M, Conti F, Maccauro G, et al. (2012) IL-37 (IL-1F7) the newest anti-inflammatory cytokine which suppresses immune responses and inflammation. Int J Immunopathol Pharmacol 25:31-38.
25. Song L, Qiu F, Fan Y, Ding F, Liu H, et al. (2013) Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 33:111-117.
26. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, et al. (2002) The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 41:329-337.
27. Md Yusof MY, Emery P (2013) Targeting interleukin-6 in rheumatoid arthritis. Drugs 73:341-356.
28. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, et al. (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 11:R113.
29. Kramer JM, Gaffen SL (2007) Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 78:1083-1093.
30. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, et al. (2011) Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 108:16711-16716.
31. Sakai N, Van Sweringen HL, Belizaire RM, Quillin RC, Schuster R, et al. (2012) Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 27:1609-1616.
32. Bulau AM, Fink M, Maucksch C, Kappler R, Mayr D, et al. (2011) In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. Scientific World Journal 11:2480-2490.